ADC Therapeutics SA (ADCT)
↓ Download CSV- Sector Manufacturing
- Incorporated V8
- Fiscal year ends Dec 31
In fiscal 2025, ADC Therapeutics SA reported revenue of $81.36M, up 14.9% from the prior year. The company ran a net loss, with a net margin of -175.3%. It held $323.15M in total assets against $508.98M in total liabilities.
Key ratios (FY2025)
-149.3%
Operating margin
-175.3%
Net margin
+14.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $81.36M | $70.84M | $69.56M | $209.91M | — |
| Cost of Revenue | $5.80M | $5.95M | $2.53M | $3.30M | — |
| Operating Income | -$121.50M | -$130.65M | -$165.99M | -$123.34M | — |
| Net Income | -$142.62M | -$157.85M | -$240.05M | -$157.13M | — |
| EPS (Diluted) | $-1.12 | $-1.62 | $-2.94 | $-2.01 | — |
| Total Assets | $323.15M | $321.98M | $354.78M | $490.86M | — |
| Total Liabilities | $508.98M | $524.62M | $503.03M | $411.41M | — |
| Shareholders' Equity | -$185.83M | -$202.64M | -$148.25M | $79.45M | $154.03M |
| Cash & Equivalents | $261.34M | $250.87M | $278.60M | $326.44M | — |
| Operating Cash Flow | -$141.17M | -$123.83M | -$118.69M | -$138.31M | — |
| Capital Expenditures | $264.0K | $867.0K | $3.22M | $687.0K | — |
| Shares Outstanding | 125.75M | 98.86M | 82.29M | 80.64M | — |